Get started
Author

Hikmat Al‐Hashimi

Observed names: H. Al-Hashimi, Hikmat Al-Hashimi, Hikmat I. Al-Hashimi
ORCID: 0000-0001-5999-2874
Observed ORCID: 0000-0001-5999-2874
OpenAlex ID: A5038385781
Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti‐tumor efficacy
2024 · Yasmin Yu, Madhumita Bogdan, et al. · Molecular Oncology · 14
Tubular Excretory Canal Structure Depends on Intermediate Filaments EXC-2 and IFA-4 in Caenorhabditis elegans
2018 · Hikmat I. Al-Hashimi, David H. Hall, et al. · Genetics · 13
PDF
Abstract 3600: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with the KRASG12C inhibitor sotorasib resulting in tumor regression in KRAS mutant NSCLC xenograft models
2022 · Martin McMahon, Madhumita Bogdan, et al. · Cancer Research · 10
Facilitation of Endosomal Recycling by an IRG Protein Homolog Maintains Apical Tubule Structure in Caenorhabditis elegans
2016 · Kelly A Grussendorf, Christopher J Trezza, et al. · Genetics · 10
PDF
A Series of Tubes: The C. elegans Excretory Canal Cell as a Model for Tubule Development
2020 · Matthew Buechner, Zhe Yang, et al. · Journal of Developmental Biology · 9
PDF
Novel exc Genes Involved in Formation of the Tubular Excretory Canals of Caenorhabditis elegans
2019 · Hikmat Al-Hashimi, Travis Chiarelli, et al. · G3 Genes Genomes Genetics · 9
PDF
Abstract P084: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with EGFR inhibitors osimertinib and afatinib in NSCLC preclinical models
2021 · Madhumita Bogdan, Mary J. Timson, et al. · Molecular Cancer Therapeutics · 8
Abstract B129: Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers
2019 · Bryan D Smith, Lakshminarayana Vogeti, et al. · Molecular Cancer Therapeutics · 7
Abstract 4045: DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models
2023 · Stacie L. Bulfer, Bertrand Le Bourdonnec, et al. · Cancer Research · 4
Abstract 4872: DCC-3116, a first-in-class selective ULK1/2 inhibitor of autophagy, in combination with the KIT inhibitor ripretinib induces complete regressions in GIST preclinical models
2023 · Madhumita Bogdan, Mary J. Timson, et al. · Cancer Research · 3
Abstract 1377: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with encorafenib and cetuximab in BRAF V600E mutant colorectal cancer models
2023 · Madhumita Bogdan, Mary J. Timson, et al. · Cancer Research · 2
Abstract C074: VPS34 inhibition delays activation-induced STING degradation to prolong STING signaling and improve anti-tumor efficacy in preclinical models
2023 · Madhumita Bogdan, Jodi Simeon, et al. · Molecular Cancer Therapeutics · 1
Author response for "Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti‐tumor efficacy"
2024 · Yasmin Yu, Madhumita Bogdan, et al. · Publons reviews and discussion
exc-2, an intermediate filament gene, maintains tubular excretory canals in Caenorhabditis elegans along with ifa-4 and other novel genes.
2018 · Hikmat Al‐Hashimi · KU ScholarWorks (The University of Kansas)
Works count: 15
Citation count: 90
H-index: 7
I10-index: 4
Year
Topic
Type